Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLACE: Reproxalap in Non-infectious Anterior Uveitis
NCT03131154Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial comparing Reproxalap with Vehicle (2 arms). Primary endpoint: Time to Clearance of Anterior Chamber Cells at 4 weeks. Started Apr 2017; status: completed.
02
Drugs
reproxalap
Beyond the preview
Go deeper on NCT03131154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131154.